Filing Overview
This Form 6-K was filed by NLS Pharmaceutics Ltd., not Newcelx Ltd., on June 10, 2022, covering June 2022 (Report No. 5). The filing reports that the company issued a press release titled “NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification.”
Business Context and Reporting Period
NLS Pharmaceutics Ltd. is a foreign private issuer headquartered in Zurich, Switzerland, and files annual reports on Form 20-F. The filing contains the company’s cover information, a reference to the June 10, 2022 press release, and Exhibit 99.1.
Financial and Operating Metrics
- The filing text does not provide revenue, profit, cash flow, margins, debt, liquidity, operating results, or other financial metrics.
- The filing text does not state the specific Nasdaq minimum bid price deficiency, the applicable deadline, or any remediation plan.
Material Changes, Outlook, and Risks
- The principal disclosed event is receipt of a Nasdaq minimum bid price notification.
- The filing text does not provide management’s detailed commentary, guidance, outlook, contingency measures, or the potential consequences of the notification.
- The press release was furnished as Exhibit 99.1 and incorporated by reference into the company’s Form F-3 registration statement, subject to subsequent filings.
Important Facts to Verify
- Confirm that the intended issuer is NLS Pharmaceutics Ltd.; the supplied company metadata identifies Newcelx Ltd.
- Review Exhibit 99.1 for the Nasdaq notice date, minimum bid price requirement, compliance deadline, and any appeal or remediation plan.
- Assess whether the notification could lead to suspension, delisting, reverse-split action, or other capital-markets consequences.
- Check subsequent SEC filings for the company’s Nasdaq compliance status and any related corporate actions.